drugset / Trial / NCT00649194

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

NCT00649194

Phase 1 Completed 72 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets relative to Eisai's Aciphex® delayed-release 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fed conditions.

Timeline

Start
2003-08
Primary completion
2003-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg Oral

Indications

No indication recorded.